PDCD1 and AL amyloidosis: However, the combination of anti-CTLA-4 and anti-PD-1 antibodies demonstrated a similar safety and efficacy profile compared to a previous report for anti-PD-1 monotherapy in Hodgkin lymphoma, non-Hodgkin lymphoma (NHL), and multiple myeloma (19).